Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients

Novartis AG NVS has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). 

  • Results from year two of KESTREL were consistent with those seen at year one, including maintenance of best-corrected visual acuity and sustained reductions in central subfield thickness. 
  • Additionally, numerically fewer Beovu patients had intraocular fluid and/or sub-retinal fluid versus patients treated with Regeneron Pharmaceuticals Inc's REGN Eylea (aflibercept). 
  • More than 40% of Beovu patients were maintained on 12-week dosing intervals, and 70% of patients who completed the first 12-week cycle after loading remained on 12-week dosing through year two, showing the potential for Beovu to offer fluid resolution in more DME patients with fewer injections versus aflibercept.
  • Further details of year-two findings from the KESTREL trial and findings from another pivotal Phase 3 (KITE) trial of Beovu in DME will be presented at upcoming medical congresses.
  • No vascular events were reported in year two (weeks 52-100). No new retinal vasculitis (RV) events were reported during year two of KESTREL. 
  • Price Action: NVS shares are down 1.02% at $80.53 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsDiabetic Macular EdemaPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!